A. Gill
6 Papers
8 Citations
A. Gill is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
Marta Łuksza,Zachary Sethna,Luis A. Rojas,Jayon Lihm,Barbara Bravi,Yuval Elhanati,Kevin C. Soares,Masataka Amisaki,Anton Dobrin,David Hoyos,Pablo Guasp,Abderezak Zebboudj,Rebecca Yu,A. Chandra,Tracey A. Waters,Zagaa Odgerel,Joanne Leung,Rajya Kappagantula,Alvin Makohon-Moore,Amber L. Johns,A. Gill,Mathieu Gigoux,Jedd D. Wolchok,Taha Merghoub,Michel Sadelain,Erin V Patterson,Rémi Monasson,Thierry Mora,Aleksandra M. Walczak,Simona Cocco,Christine A. Iacobuzio-Donahue,Benjamin Greenbaum,Vinod P. Balachandran +32 more
TL;DR: In this article , the authors investigate how 70 human pancreatic cancers evolved over 10 years and find that rare long-term survivors of pancreatic cancer who have stronger T cell activity in primary tumours develop genetically less heterogeneous recurrent tumours with fewer immunogenic mutations (neoantigens).
Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
Venessa H M Tsang,A. Gill,Matti L Gild,Brett Lurie,Lucy Blumer,Rhonda Siddall,Roderick J. Clifton-Bligh,B. Robinson +7 more
TL;DR: Histological evidence of mucosal edema observed in conjunction with the radiological findings of congestion and wall thickening suggest bowel-wall edema is a predominant mechanism of abdominal pain in patients with thyroid cancer harboring the same oncogenic driver.
18
High incidence of hypersensitivity reactions to cetuximab infusions in mid-Missouri: Association with prior history of atopy
TL;DR: A study from the University of North Carolina and the Vanderbilt Ingram Cancer Center found that the overall rate of grade 3 or 4 hypersensitivity reactions (HSR) was 22%, much higher than the reported national and international average of less than 3%.
12
Succinate dehydrogenase-deficient renal cell carcinoma: A retrospective study, 1999–2018
Ella Morrison,Jacqueline Goedhals,S.W. Pretorius,Gina Joubert,A. Gill,Gerhard van der Westhuizen +5 more
TL;DR: The incidence of SDH-deficient renal cell carcinoma (RCC) in South Africa is unknown as mentioned in this paper , however, it is known that approximately 0.05% -0.2% of RCCs are SDH deficient.
SMARCA4-deficient non-small cell lung cancer
TL;DR: A 41-year-old male with SMARCA4 deficient metastatic non-small cell lung cancer (NSCLC) diagnosed on brain resection was reported in this paper .